Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Infants and young children with atopic dermatitis experienced improvements in signs and symptoms with dupilumab treatment regardless of other type 2 comorbidities, according to a study published ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, according to a ...

Median changes from Part A baseline to week 52 in type 2 NES in Part C were –1.94 and –1.97 for patients initiated on placebo who switched to dupilumab at week 24 and those on dupilumab for ...

Serious adverse events remained rare and skin remained largely clear in adolescents treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a phase 3 ...

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Published Sep 13, 2024 12:15pm EDT ...

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. New England Journal of Medicine, 2021; 385 (24): 2230 DOI: 10.1056/NEJMoa2106567 ...

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma ...